share_log

Viracta Therapeutics | 8-K: Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

SEC ·  May 9, 2023 04:23
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.